LLY vs MRNA
Eli Lilly vs Moderna stock: which is the better buy?
Tickerday reads Eli Lilly as a Buy at 70 and Moderna as a Hold at 48. Today, Eli Lilly is the stronger call.
Try it on the stock you're thinking about. First one free, no account needed.
LLY
Eli Lilly
Buy70/100
Sunny, with 78% confidence
A year from now: $1,455 (+15.0%)
MRNA
Moderna
Hold48/100
Partly cloudy, with 55% confidence
A year from now: $50 (−21.9%)
Under the hood
Factor by factor
The six things Tickerday weighs, each scored 0 to 100. The higher of each pair is in its call's color.
Eli Lilly
Moderna
Overall score
Valuation
Growth
Profitability
Momentum
Financial Health
Sentiment
Where they're headed
Price targets
Each target is measured from the price on the day its stock was read.
Eli Lilly
Moderna
Price when read
LLY$1,265 · Oct 15, 2026
MRNA$63.98 · Jun 19, 2026
Next week
LLY$1,284 (+1.5%)
MRNA$63 (−1.5%)
Next month
LLY$1,315 (+4.0%)
MRNA$65 (+1.6%)
Next year
LLY$1,455 (+15.0%)
MRNA$50 (−21.9%)
The numbers
Key numbers
Eli Lilly
Moderna
Market Cap
LLY$1.17T
MRNA$25.4B
P / E Ratio
LLY43.8
MRNA—
Rev. Growth
LLY+49.6%
MRNA-30.0%
Net Margin
LLY+33.5%
MRNA-143.6%
Debt / Equity
LLY1.62
MRNA0.09
Dividend Yield
LLY0.5%
MRNA—
Beta
LLY0.42
MRNA0.90
52-Wk Range
LLY$784 – $1293
MRNA$22 – $68
The argument
The case for and against
Every call has a case against it. Here are both sides, for each stock.
Eli Lilly LLY
The case for
- Explosive revenue growth of nearly 50% year-over-year, driven by its wildly successful drug pipeline.
- Exceptional profitability, with a net margin over 33%, turning a large portion of sales into profit.
The case against
- The stock trades at a high valuation (P/E of 43.8), meaning very high expectations are already priced in.
- The company carries a notable amount of debt, with a Debt-to-Equity ratio of 1.62.
Moderna MRNA
The case for
- The stock has shown very strong price momentum, more than doubling from its 52-week low.
- With a very low debt-to-equity ratio of 0.09, the company has a fortress-like balance sheet to fund future research.
The case against
- Revenue has fallen by 30% over the last year, a significant headwind as vaccine sales have slowed.
- The company is currently not profitable, reporting significant losses per share.
Tickerday's reads are educational analysis, the same for everyone, not financial advice. Eli Lilly was read on Oct 15, 2026 and Moderna on Jun 19, 2026; each one's page has the full forecast.
Comparing stocks takes hours.
Tickerday takes seconds.
Now try yours
What about your stocks?
You just compared Eli Lilly and Moderna. Type a company you own and get its call, and the why, in seconds. First one free, no account needed.
The receipts
Called it. Then it happened.
Real calls from the Tickerday engine, each one graded against the real price a month later.
Every call is graded
One month after the call, at the closing price.
Palantir Technologies Inc
+52.3%
✓Called it
We said Buy at $122.33 on Jul 30. A month later the price was $186.29.
Graded Aug 28 at the closing price
One blind call costs more
than a year of Tickerday.
Pricing
Start free, right here
Your first analysis is free, no account needed. Tickerday+ takes it from there.
Tickerday+
Pro
Built for fast clarity.
- Clear buy / hold / sell-style insights
- Key risks and opportunities
- Focused market analysis
- 40 priority credits every month
Billed monthly · ≈ $0.30/day
Tickerday+
Most popularPremium
The full why, explained.
- Expanded analysis & learning depth
- Interactive explanations & breakdowns
- Tap to understand key metrics & terms
- 100 priority credits every month
Billed yearly · ≈ $14.08/mo≈ $0.46/day
Cancel anytime.
FAQ
Good questions
Coming soon to the App Store
The market never sleeps.
That doesn't mean you shouldn't get to.
The Tickerday app is almost here — watchlists, daily check-ins, weather-change alerts, and an Almanac that keeps score of every call. We'll watch the market while you sleep, so you never fly blind again.
Free to download the day it lands — the web desk is open now